PAOX — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL715423	0.62	6/20
SCHEMBL285321	1.00	5/20
SCHEMBL346746	1.00	5/20
SCHEMBL64860	0.72	5/20
SCHEMBL316713	0.72	5/20
SCHEMBL749119	0.72	5/20
SCHEMBL620309	0.67	5/20
SCHEMBL169164	0.59	5/20
SCHEMBL506038	0.59	5/20
SCHEMBL148224	0.54	5/20
SCHEMBL379594	0.50	5/20
Trientine (SCHEMBL732582)	0.44	5/20
SCHEMBL183048	0.80	4/20
SCHEMBL183049	0.76	4/20
SCHEMBL193116	0.73	4/20
SCHEMBL608623	0.65	4/20
SCHEMBL110911	0.64	4/20
SCHEMBL152548	0.62	4/20
SCHEMBL285151	0.62	4/20
SCHEMBL476851	0.62	4/20

Clinical trials — most relevant to PAOX by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone	PHASE4	COMPLETED
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.	PHASE4	COMPLETED
Omega 3 and Ischemic Stroke; Fish Oil as an Option	PHASE4	UNKNOWN
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	PHASE3	COMPLETED
Betaine and Peroxisome Biogenesis Disorders	PHASE3	COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	PHASE3	COMPLETED
Role of Vitamin E in Gaucher Disease Patients	PHASE3	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)	PHASE2	RECRUITING
Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout	PHASE2	UNKNOWN
Electrophilic Fatty Acid Derivatives in Asthma	PHASE1	COMPLETED
A Supervised Nutritional Program in Pregnancies and NF-κB Expression in Placenta	PHASE1	COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease	EARLY_PHASE1	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.	nan	COMPLETED
Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function	nan	UNKNOWN
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	nan	NOT_YET_RECRUITING
Exercise Intolerance Study in Long Chain Fatty Acid Oxidation Disorders	nan	RECRUITING
Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases	nan	COMPLETED
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
Saturated Fat Versus Monounsaturated Fat and Insulin Action	nan	COMPLETED
A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis	nan	UNKNOWN
Identification of Gulf War Illness (GWI) Biomarkers	nan	COMPLETED
Effect of Tahini in Oxidative Stress and Endothelial Function in Diabetes	nan	COMPLETED
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism	nan	UNKNOWN
Tahini, Antioxidant Status and Endothelial Function	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PAOX binder may also engage these)

Protein	Name	Similarity
Q865R1	—	1.000	Q865R1 →
Q8C0L6	—	1.000	Q8C0L6 →
Q6NUM9	—	0.981	Q6NUM9 →
Q3UZW7	—	0.979	Q3UZW7 →
P10937	—	0.978	P10937 →
Q8NBM8	—	0.977	Q8NBM8 →
P0C5J1	—	0.976	P0C5J1 →
Q91ZJ0	—	0.976	Q91ZJ0 →
Q8R123	—	0.976	Q8R123 →
Q8BYR1	—	0.976	Q8BYR1 →
O95479	—	0.976	O95479 →
Q8CGS5	—	0.976	Q8CGS5 →
Q86TX2	—	0.976	Q86TX2 →
Q8VDP3	—	0.976	Q8VDP3 →
Q8CFX1	—	0.976	Q8CFX1 →
FLAD1	FAD synthase	0.976	landscape →
B3DLB3	—	0.975	B3DLB3 →
Q5XIA3	—	0.975	Q5XIA3 →
Q86U10	—	0.975	Q86U10 →
Q68DD2	—	0.975	Q68DD2 →
Q64FG0	—	0.975	Q64FG0 →
Q8HY87	—	0.975	Q8HY87 →
Q5NVK5	—	0.975	Q5NVK5 →
P56201	—	0.975	P56201 →
Q1JPJ9	—	0.975	Q1JPJ9 →
P10938	—	0.975	P10938 →
Q8MIR4	—	0.975	Q8MIR4 →
Q8VDG7	—	0.975	Q8VDG7 →
Q8C7K6	—	0.974	Q8C7K6 →
Q8QZW3	—	0.974	Q8QZW3 →